CURE Childhood Cancer’s mission is to conquer childhood cancer through funding targeted research while supporting patients and their families. CURE invests millions of dollars each year into the most promising childhood cancer research, working to ensure children have the best chance to survive their cancer without sacrificing their future health and quality of life.
For 2023, CURE will offer two different types of research grants: Translation to Cure (T2C) award and a new Early Investigator (EI) award.
- Translation to CURE award (T2C) – open to investigators at any stage of their career (Assistant to Full Professor). The award term will be up to 2 years with support of $150,000 per year in direct costs plus 10% indirect costs (Total award = $330,000).
- Early Investigator award (EI) – open to beginning scientists and physician scientists at the Instructor or Assistant Professor level. Physician scientists (MD or MD/PhD) who are within 5 years of completion of their clinical (or terminal) fellowship training and are beginning to establish a research career may apply as Instructors or Assistant Professors. PhD scientists within 5 years of an initial appointment as a tenure track Assistant Professor are also invited to apply for this award. 2-3 EI awards will be made in 2023. The award term will be up to 2 years with support of $100,000 per year in direct costs plus 10% indirect costs (Total award = $220,000).
